Chester County News and Community Website
WILMINGTON, DE — Prelude Therapeutics Inc. (Nasdaq: PRLD) reported its financial results for the year ended December 31, 2025, and provided updates on its oncology drug development pipeline, including regulatory …
Prelude Therapeutics Reports 2025 Results and Advances Oncology Pipeline Read More WILMINGTON, DE — Prelude Therapeutics Incorporated (Nasdaq: PRLD) said the U.S. Food and Drug Administration has cleared its investigational new drug application for PRT12396, allowing the company to begin a …
FDA Clears Prelude’s Experimental Cancer Drug, Opening New Path for Blood Disorders Read More WILMINGTON, DE — Prelude Therapeutics Incorporated (Nasdaq: PRLD) reported third-quarter 2025 financial results and outlined key progress across its oncology pipeline, including two drug candidates now moving toward clinical development …
Prelude Advances Two Novel Cancer Programs as Cash Runway Extends Into 2027 Read More WILMINGTON, DE — Prelude Therapeutics Incorporated (Nasdaq: PRLD) announced a series of strategic updates aimed at sharpening its development priorities and extending its financial runway. The biotechnology company has executed …
Prelude Therapeutics Reshapes Pipeline With Incyte Deal and Strategic Refocus Read More WILMINGTON, DE — Prelude Therapeutics Incorporated (Nasdaq: PRLD) has entered into an exclusive option agreement with Incyte Corporation (Nasdaq: INCY) for its mutant-selective JAK2V617F JH2 inhibitor program, a next-generation therapy …
Prelude Strikes $910 Million Deal With Incyte for Groundbreaking JAK2 Cancer Therapy Read More WILMINGTON, DE — Prelude Therapeutics Incorporated (Nasdaq: PRLD) announced the publication of two abstracts featuring preclinical data from its JAK2V617F mutant-selective inhibitor program and CALR-targeted degrader antibody conjugates (DACs) discovery …
Prelude Therapeutics Highlights Groundbreaking Blood Cancer Research at ASH 2025 Read More WILMINGTON, DE — Prelude Therapeutics Incorporated (Nasdaq: PRLD) announced the appointment of Katina Dorton to its Board of Directors, effective immediately. Dorton brings more than 30 years of experience in …
Prelude Therapeutics Appoints Katina Dorton to Board of Directors Read More WILMINGTON, DE — Prelude Therapeutics Incorporated (Nasdaq: PRLD) has shifted its strategic focus toward its oral SMARCA2 degrader, PRT7732, while reporting narrower second-quarter losses and steady progress across its oncology …
Prelude Therapeutics Refocuses SMARCA2 Program, Cuts Quarterly Losses Read More WILMINGTON, DE — Prelude Therapeutics Incorporated (Nasdaq: PRLD) announced it will participate in two healthcare conferences in June.
Prelude Therapeutics to Present at Major Healthcare Conferences in June 2025 Read More WILMINGTON, DE — Prelude Therapeutics Incorporated (Nasdaq: PRLD) released its first-quarter financial results, showcasing operational progress and updates across its clinical pipeline.
Prelude Therapeutics Reports Q1 2025 Financial Results and Progress on Clinical Programs Read More